NCT03771859Completed
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
An Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma
Source: ClinicalTrials.gov · Last updated 2 Jun 2026
Brief summary (registry, in English)
An observational study of melanoma participants who are eligible for and who have initiated treatment with adjuvant nivolumab as part of routine clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 152 (actual)
- First submitted
- 10 Dec 2018
- Start date
- 16 Jan 2019
- Primary completion date
- 9 Dec 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Melanoma
- NCT number
- NCT03771859
What you commit to
- Study type: Observational
- Participants enrolled: 152
- From 16 Jan 2019 to the primary completion date, 9 Dec 2025
- 14 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any patient with a diagnosis of persisting advanced melanoma prior to first administration of nivolumab
- Any patient currently enrolled in an interventional clinical trial for his/her melanoma treatment (note: patients who have completed their participation in an interventional trial or who are no longer receiving the study drug and are only followed up for Overall Survival (OS)/ Relapse Free Survival (RFS) can be enrolled. In case of a blinded study, the treatment arm needs to be known).
- Other protocol defined inclusion/exclusion criteria could apply
Who the study is looking for
- Patients with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection and have no evidence of disease.
- Decision to treat with adjuvant nivolumab therapy has already been taken
- At least 18 years of age at the time of treatment decision
- Patients who provide written informed consent to participate in the study (for retrospectively enrolled patients who are deceased at time of study start, a consent waiver will be sought)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.